Spark Therapeutics, Inc. (ONCE) Forecasted to Earn Q4 2017 Earnings of ($1.71) Per Share
Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at Wedbush upped their Q4 2017 earnings per share estimates for shares of Spark Therapeutics in a research note issued on Wednesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of ($1.71) for the quarter, up from their previous estimate of ($1.96). Wedbush also issued estimates for Spark Therapeutics’ Q1 2018 earnings at ($1.96) EPS, Q2 2018 earnings at ($1.93) EPS, Q3 2018 earnings at ($1.91) EPS, Q4 2018 earnings at ($1.85) EPS, FY2018 earnings at ($7.65) EPS, FY2019 earnings at ($5.54) EPS, FY2020 earnings at ($2.85) EPS and FY2021 earnings at $0.91 EPS.
A number of other research analysts have also issued reports on ONCE. ValuEngine lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. BMO Capital Markets reiterated an “outperform” rating and set a $89.00 price target (up from $69.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $60.00 to $100.00 in a research note on Tuesday, August 8th. SunTrust Banks, Inc. set a $101.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Cowen and Company reiterated an “outperform” rating and set a $95.00 price target (up from $75.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $90.36.
WARNING: “Spark Therapeutics, Inc. (ONCE) Forecasted to Earn Q4 2017 Earnings of ($1.71) Per Share” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/14/spark-therapeutics-inc-once-forecasted-to-earn-q4-2017-earnings-of-1-71-per-share.html.
Spark Therapeutics (NASDAQ:ONCE) opened at $72.65 on Monday. Spark Therapeutics has a one year low of $47.03 and a one year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in ONCE. BlackRock Inc. lifted its stake in shares of Spark Therapeutics by 11,332.0% during the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Spark Therapeutics during the second quarter valued at approximately $30,848,000. Jennison Associates LLC purchased a new position in shares of Spark Therapeutics during the third quarter valued at approximately $27,239,000. JPMorgan Chase & Co. lifted its stake in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after buying an additional 241,016 shares during the period. Finally, Sectoral Asset Management Inc purchased a new position in shares of Spark Therapeutics during the second quarter valued at approximately $6,052,000. 77.94% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Daniel Faga sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.02, for a total transaction of $255,060.00. Following the transaction, the insider now owns 3,000 shares of the company’s stock, valued at $255,060. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $81.00, for a total transaction of $445,500.00. Following the transaction, the insider now directly owns 10,825 shares in the company, valued at approximately $876,825. The disclosure for this sale can be found here. Insiders sold 1,099,659 shares of company stock worth $92,457,658 in the last ninety days. Insiders own 7.30% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.